A U.S. appeals court added more weight to the argument that pharma sales reps are entitled to overtime pay. Overturning a lower court ruling, the three-judge panel in New York ruled that Novartis sales folks aren’t exempt from wage-and-hour laws because they’re neither true outside sales people nor administrative…
Genzyme sued Impax Laboratories for patent infringement after Impax filed for FDA approval of a copycat version of the kidney dialysis drug Renvela. Report
Original Source of Genzyme, Impax begin Revela patent fight
What if that old story about U.S. drug prices beating all others
Don’t count Eli Lilly out of the hunt for acquisitions. CEO John Lechleiter told the Swiss newspaper Finanz und Wirtschaft over the weekend that he’s open to smaller-sized buyouts, about the size of the Imclone deal two years ago. You’ll recall that the Imclone buyout ran to $6.5 billion….
Top drug websites are like Alice in Wonderland’s rabbit hole, a new analysis finds, you never know where they might take you. Two academic researchers took a look at the websites of the 100 best-selling drugs and found a navigational “maze” and a confusing mix of information and marketing….
Are drugmakers getting the antitrust message in Europe? If a new European Commission survey is any indication, they are. Regulators have sifted through patent settlements from July 2008 to December 2009 and found only nine
28 – 29 September 2010, Milan, Italy. After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.
Original Source of 6th Annual Project &…
AstraZeneca and MRC Technology, the commercialisation company for the UK’s Medical Research Council, announced a new strategic collaboration to share access to their collections of compounds to aid the search for potential new treatments for serious diseases.
Original Source of AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research…
Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) announced that Ranbaxy’s New Drug Discovery Research (“NDDR”) has been transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development (R&D) structure of the Daiichi Sankyo Group.
Original Source…
The U.K.’s cost-effectiveness watchdog changed its mind to recommend Roche’s arthritis drug RoActemra for use by the National Health Service, but it rejected the use of Novartis’ Afinitor in patients with kidney cancer. Report | Report
Original Source of NICE greenlights RoActemra, snubs Afinitor